These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
450 related items for PubMed ID: 10540190
1. Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages. Revelli S, Le Page C, Piaggio E, Wietzerbin J, Bottasso O. Clin Exp Immunol; 1999 Nov; 118(2):271-7. PubMed ID: 10540190 [Abstract] [Full Text] [Related]
2. Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. Pascutti MF, Pitashny M, Nocito AL, Guermonprez P, Amigorena S, Wietzerbin J, Serra E, Bottasso O, Revelli S. Life Sci; 2004 Dec 24; 76(6):685-97. PubMed ID: 15567193 [Abstract] [Full Text] [Related]
3. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Muñoz-Fernández MA, Fernández MA, Fresno M. Eur J Immunol; 1992 Feb 24; 22(2):301-7. PubMed ID: 1537373 [Abstract] [Full Text] [Related]
4. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain. Cevey ÁC, Mirkin GA, Penas FN, Goren NB. Int J Parasitol Drugs Drug Resist; 2016 Apr 24; 6(1):12-22. PubMed ID: 26862474 [Abstract] [Full Text] [Related]
5. Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Piaggio E, Roggero E, Pitashny M, Wietzerbin J, Bottasso OA, Revelli SS. Parasitol Res; 2001 Jul 24; 87(7):539-47. PubMed ID: 11484850 [Abstract] [Full Text] [Related]
6. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon-gamma-stimulated RAW 264.7 cells: the role of tumor necrosis factor-alpha. Murakami A, Kawabata K, Koshiba T, Gao G, Nakamura Y, Koshimizu K, Ohigashi H. Cancer Res; 2000 Nov 15; 60(22):6326-31. PubMed ID: 11103793 [Abstract] [Full Text] [Related]
7. Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-kappaB activation. Piaggio E, Sancéau J, Revelli S, Bottasso O, Wietzerbin J, Serra E. J Immunol; 2001 Sep 15; 167(6):3422-6. PubMed ID: 11544334 [Abstract] [Full Text] [Related]
8. Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Machado FS, Martins GA, Aliberti JC, Mestriner FL, Cunha FQ, Silva JS. Circulation; 2000 Dec 12; 102(24):3003-8. PubMed ID: 11113053 [Abstract] [Full Text] [Related]
9. Benznidazole Anti-Inflammatory Effects in Murine Cardiomyocytes and Macrophages Are Mediated by Class I PI3Kδ. Cevey ÁC, Mascolo PD, Penas FN, Pieralisi AV, Sequeyra AS, Mirkin GA, Goren NB. Front Immunol; 2021 Dec 12; 12():782891. PubMed ID: 34925364 [Abstract] [Full Text] [Related]
10. Human renal epithelial cells express iNOS in response to cytokines but not bacteria. Poljakovic M, Karpman D, Svanborg C, Persson K. Kidney Int; 2002 Feb 12; 61(2):444-55. PubMed ID: 11849384 [Abstract] [Full Text] [Related]
11. In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population. Murta SM, Ropert C, Alves RO, Gazzinelli RT, Romanha AJ. Parasite Immunol; 1999 Oct 12; 21(10):535-44. PubMed ID: 10610497 [Abstract] [Full Text] [Related]
12. Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release. Fichera LE, Albareda MC, Laucella SA, Postan M. Infect Immun; 2004 Jan 12; 72(1):359-63. PubMed ID: 14688116 [Abstract] [Full Text] [Related]
13. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. Kolios G, Brown Z, Robson RL, Robertson DA, Westwick J. Br J Pharmacol; 1995 Dec 12; 116(7):2866-72. PubMed ID: 8680718 [Abstract] [Full Text] [Related]
14. Regulation of lipopolysaccharide-induced NO synthase expression in the major organs in a mouse model. The roles of endogenous interferon-gamma, tumor necrosis factor-alpha and interleukin-10. ter Steege JC, van de Ven WC, Forget PP, Buurman WA. Eur Cytokine Netw; 2000 Mar 12; 11(1):39-46. PubMed ID: 10705297 [Abstract] [Full Text] [Related]
15. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Hölscher C, Köhler G, Müller U, Mossmann H, Schaub GA, Brombacher F. Infect Immun; 1998 Mar 12; 66(3):1208-15. PubMed ID: 9488415 [Abstract] [Full Text] [Related]
16. Adrenaline suppression of the macrophage nitric oxide response to lipopolysaccharide is associated with differential regulation of tumour necrosis factor-alpha and interleukin-10. Zinyama RB, Bancroft GJ, Sigola LB. Immunology; 2001 Dec 12; 104(4):439-46. PubMed ID: 11899430 [Abstract] [Full Text] [Related]
17. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection. Abrahamsohn IA, Coffman RL. Exp Parasitol; 1996 Nov 12; 84(2):231-44. PubMed ID: 8932773 [Abstract] [Full Text] [Related]
18. IL-10 up-regulates nitric oxide (NO) synthesis by lipopolysaccharide (LPS)-activated macrophages: improved control of Trypanosoma cruzi infection. Jacobs F, Chaussabel D, Truyens C, Leclerq V, Carlier Y, Goldman M, Vray B. Clin Exp Immunol; 1998 Jul 12; 113(1):59-64. PubMed ID: 9697984 [Abstract] [Full Text] [Related]
19. The microbicidal activity of interferon-gamma-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-beta. Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A. Eur J Immunol; 1992 Oct 12; 22(10):2501-6. PubMed ID: 1396957 [Abstract] [Full Text] [Related]
20. Anti-inflammatory and antioxidative effects of propofol on lipopolysaccharide-activated macrophages. Chen RM, Chen TG, Chen TL, Lin LL, Chang CC, Chang HC, Wu CH. Ann N Y Acad Sci; 2005 May 12; 1042():262-71. PubMed ID: 15965071 [Abstract] [Full Text] [Related] Page: [Next] [New Search]